Bruton's tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential
efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new …

Follicular lymphoma (FL) is a systemic neoplasm of the lymphoid tissue displaying germinal
centre (GC) B cell differentiation. FL represents~ 5% of all haematological neoplasms and …

PURPOSE Patients with indolent non-Hodgkin lymphoma typically respond well to first-line
immunochemotherapy. At relapse, single-agent rituximab is commonly administered. Data …

Background Rituximab plus chemotherapy has been shown to be effective in patients with
advanced-stage, previously untreated follicular lymphoma; nevertheless, most patients will …

Extranodal marginal zone (MZ) B-cell lymphomas of the mucosa-associated lymphoid tissue
(MALT) arise from lymphoid populations that are induced by chronic inflammation in …

Lenalidomide is an orally active immunomodulatory drug that has direct antineoplastic
activity and indirect effects mediated through multiple types of immune cells found in the …

Non-Hodgkin lymphomas are lymphoid malignant neoplasms with diverse biological and
clinical behavior. Patients typically present with persistent painless lymphadenopathy, but …

Therapeutic monoclonal antibodies (mAbs) have become one of the fastest growing classes
of drugs in recent years and are approved for the treatment of a wide range of indications …

Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma in the
Western hemisphere. After decades of stagnation, the natural history of FL appears to have …

Splenic marginal zone lymphoma (SMZL) is a rare B-cell malignancy involving the spleen,
bone marrow, and frequently the blood. SMZL lymphomagenesis involves antigen and/or …